Rempart Asset Management Inc. Sells 3,172 Shares of Becton, Dickinson and Company $BDX

Rempart Asset Management Inc. trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 95,242 shares of the medical instruments supplier’s stock after selling 3,172 shares during the period. Becton, Dickinson and Company makes up 3.3% of Rempart Asset Management Inc.’s investment portfolio, making the stock its 19th largest holding. Rempart Asset Management Inc.’s holdings in Becton, Dickinson and Company were worth $17,826,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the stock. SOA Wealth Advisors LLC. grew its holdings in Becton, Dickinson and Company by 256.8% in the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 95 shares during the period. Bell Investment Advisors Inc boosted its position in shares of Becton, Dickinson and Company by 474.1% during the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 128 shares in the last quarter. Bank of Jackson Hole Trust grew its stake in shares of Becton, Dickinson and Company by 85.6% in the 2nd quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after buying an additional 95 shares during the period. CVA Family Office LLC increased its position in Becton, Dickinson and Company by 79.5% in the 2nd quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock valued at $38,000 after buying an additional 97 shares in the last quarter. Finally, CoreFirst Bank & Trust acquired a new position in shares of Becton, Dickinson and Company during the second quarter worth approximately $38,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $202.65 on Tuesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. Becton, Dickinson and Company has a fifty-two week low of $162.29 and a fifty-two week high of $251.99. The firm has a market cap of $57.74 billion, a PE ratio of 34.76, a price-to-earnings-growth ratio of 2.24 and a beta of 0.23. The business has a 50 day moving average price of $193.62 and a 200-day moving average price of $188.59.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The company had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Equities research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 8th were issued a dividend of $1.05 per share. The ex-dividend date was Monday, December 8th. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 72.04%.

Insider Buying and Selling

In related news, EVP Michael David Garrison sold 629 shares of the firm’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $196.03, for a total value of $123,302.87. Following the completion of the sale, the executive vice president owned 13,105 shares of the company’s stock, valued at $2,568,973.15. This trade represents a 4.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Bertram L. Scott sold 217 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the transaction, the director directly owned 35,816 shares in the company, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,052 shares of company stock valued at $201,235 in the last ninety days. 0.40% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Morgan Stanley lifted their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Stifel Nicolaus lifted their price target on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Royal Bank Of Canada increased their target price on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a research note on Wednesday, December 17th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group increased their target price on Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, December 10th. Four investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $207.64.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.